In breast cancer, it was found that curcumin combined with herceptin (trastuzumab) was effective against herceptin-resistant breast cancer cells, likely mediated by the decreased levels of HER-2 oncoprotein and phosphorylated Akt (Lai et al., 2012). Here, ERBB2 is linked to breast carcinoma.